Toluene, an industrial organic solvent, is voluntarily inhaled as drug of abuse.
Introduction
Inhalant abuse has increased dramatically especially in the young over the last decade globally. Survey results consistently show that nearly 20 percent of children in middle school and high school have experimented with inhaled substances (Anderson and Loomis 2003) . Furthermore, large numbers of inhalant abusers are young women in their childbearing years, therefore there are rising concerns about the potential negative impact of intentionally inhaled organic solvents on the unborn.
Among organic volatile substances, toluene is highly preferred by abusers because of its euphoric effect, cheapness and easy availability. One source, resulting in especially high exposure rates of toluene, is sniffing glue. Abuse of toluene by pregnant women can lead to an embryopathy also referred to as fetal solvent syndrome. Characteristics of toluene embryopathy include particular craniofacial features, growth retardation and central nervous system dysfunctions, such as microencephaly, brain malformation, and motor and intellectual disability (Pearson et al. 1994) . Nevertheless, not all exposed offspring show evident physical features and structural damage. Those who exposed lower doses of toluene might still have important but subtle impairment in synaptic circuitry, reflecting as neurobehavioral disturbance.
The nicotinic acetylcholine receptors (nAChRs) are expressed very early in the nervous system, where they are not only finely regulated during CNS development but probably actively contribute to it. It has been reported that nAChRs are necessary for the normal development of the visual system and sensory cortex, suggesting that adequate nAChR activation in other brain areas during development may be essential for the anatomical and functional maturation of cerebral neuronal circuits (Gotti and Clementi 2004; Moretti et al. 2004) . Experimental evidence indicates that toluene (50 µM to 10 mM) produces a reversible, concentration-dependent inhibition of 4 acetylcholine-induced current in Xenopus oocytes expressing various nicotinic receptor subtypes and ACh-mediated responses in hippocampal neurons (Bale et al. 2002) . In addition, toluene shows potent anticonvulsant effect on nicotine-induced seizures (Chan et al. 2006) . It is possible that the inhibitory effect of toluene on nAChRs is associated with the pathophysiology of neurobehavioral disorders related to developmental toluene exposure.
Recent studies have demonstrated that the pathological and behavioral effects of CNS acting chemicals, such as alcohol, MK-801, and diazepam, on the developing animals depend strongly on the developmental stage during exposure (Ikonomidou et al. 2000; Ikonomidou et al. 1999) . The period of synaptogenesis, also known as the brain growth spurt, represents the developmental period during which many components of the developing brain are known to be particularly vulnerable to neurotoxicants. The brain growth spurt occurs largely during the third trimester of human fetal development, but occurs during the early postnatal period in the rats (Dobbing and Sands 1979) . In addition, the brain undergoes considerable sculpting and remodeling during adolescence. It is also a time of extensive pruning of synapses and of reorganization of many neurotransmitter systems. In a rat model, postnatal days (PN) 28 to 42 have been conservatively defined as prototypic adolescence based on timing of age-specific behavioral changes, neural changes in brain, puberty, and the growth spurt. However, some harbingers of adolescence may begin in females as early as PN23 or so (Spear 2000) . In most previous studies on toluene abuse embryopathy, animals were exposed to toluene in gestation (Bowen et al. 2005; Hougaard et al. 1999; Thiel and Chahoud 1997) . This period is prior to the time of brain growth spurt. Therefore, the aim of the present study was to examine whether toluene exposure during brain growth spurt and early adolescence produces persistent dysfunction of nAChRs using several pharmacological and behavioral tests. For that, 5 the nicotine-induced various pharmacological effects measures (antinociception, hypothermia, and seizures) in toluene-treated and control animals were compared. A wide range of nicotinic effects is important to consider because it is believed that various nicotinic receptor subtypes mediate different pharmacological effects of nicotine. Thus, we evaluated if the levels of @4, A2 and @7 nicotinic receptor subunits in various brain regions were altered in parallel with behavioral changes.
Materials and Methods

Materials
Toluene (HPLC grade, 99.8%) was obtained from Mallinckrodt Baker (Kentucky, USA). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Animal treatment
Pregnant female Sprague-Dawley rats were supplied from the Laboratory Animal Center of Tzu Chi University (Hualien, Taiwan). Rats were housed individually on a 12/12 light-dark cycle (lights on 0700 h) at 22°C. All experiments were performed in accordance with the Republic of China animal protection law (Chapter III: Scientific Application of Animals) and approved by Review Committee of the Tzu Chi University.
Toluene exposure during the brain growth spurt
The day of birth was considered to be postnatal day (PN) 0. On PN 4, the litters were culled to 10-12 pups of equal sexes and each litter was randomly assigned to toluene or control group. The toluene animals received 500 mg/kg of toluene (0.1 g/ml in corn 6 oil) by intraperitoneal injection and the control animals received corn oil (0.1 ml/10 g) daily over PN 4-9. Toluene at the dose of 500 mg/kg did not produce significant effect on body weight. This treatment protocol is appropriate and able to mimic the toluene exposure during the brain growth spurt for the fetus of pregnant toluene abusers since the blood toluene concentrations taken from the rats subjected to a similar toluene exposure dose and paradigm (PN4-9) are in the range obtained from toluene abusers (Lee et al. 2005) . Moreover, the dose of toluene (500 mg/kg) used in the present studies produced locomotor hyperactivity, motor incoordination and occasional ataxia in the adult rats similar to the behavioral signs evoked by toluene inhalation (5000-8000 ppm) (Beyer et al. 2001; Hinman 1987) . It is estimated that abusers may inhale from 4000 to 12000 ppm toluene, taking multiple inhalation over several miniutes. This repetitive dosing may continue for hours. Actually, the brain toluene level reached the peak at 30 min after intraperetoneal injection and returned to the basal level after 2-3 h (Honma and Suda 2004; Win-Shwe et al. 2007 ). The placenta penetration efficiency for toluene is great than 90% (Shumilina 1991). It appears that our treatment protocol is able to mimic the toluene exposure by adolescents and during brain growth spurt for the fetus of pregnant abusers.
A modified 26 G needle (6 mm long) was used for the pups to prevent tissue damage. The mother did not reject the pups treated with toluene. Seven litters were used for each treatment group. One male and one female animals were randomly selected from each litter for each behavioral test on PN 56-60. Each animal was only used for one test. Body weight gain was measured over PN 4-9.
Toluene exposure during adolescence
As for the brain growth spurt experiment, the day of birth was considered PN 0 and the litters were culled to 10-12 pups of equal sexes on PN 4. The animals were 
Behavioral tests
Nicotine hydrogen tartrate were dissolved in saline and injected intraperitoneally.
For both PN 4-9 and PN 25-30 treated animals the doses of nicotine used in the following behavioral tests were chosen based on the effectiveness in our preliminary studies (data not shown).
Body Temperature
Rectal temperature was measured by a thermistor probe and digital thermometer (Singa Instrument Co., Taiwan). Readings were taken just before and after injection of nicotine (3 mg/kg, i.p.) per 10 min interval for 40 min. The nicotine-induced body temperature change was calculated by the difference in rectal temperature before and after treatment for each rat.
Hot-Plate Test
Rats were placed into a 30-cm-wide Plexiglas cylinder on a hot-plate maintained at 52±0.1°C. The time between placement and jumping or licking its paws was 
Western blotting
After decapitation, the brains were immediately removed and the brain regions were rapidly dissected out on ice. The samples were homogenized in ice-cold homogenization buffer (50 mM Tris-HCl, 5 mM EDTA, 10 mM EGTA, 0.3% (w/v) -mercaptoethanol, 10 µg/ml leupetin and 1 mM phenylmethylsulfonyl fluoride, pH 7.5). The protein concentrations of homogenates were determined using the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Equal amounts of proteins were boiled for 5 min after dilution with sample buffer. Proteins were separated by electrophoresis through a 10 % SDS-polyacrylamide gel and transferred electrophoretically to a nitrocellulose membrane. The NMDA receptor subunits were detected by the amplified alkaline phosphatase Immuno-Blot assay system (Bio-Rad, Hercules, CA).
The membranes were incubated with 5% non-fat dry milk in Tris-buffered saline (TBS: 20 mM Tris, 500 mM NaCl, pH 7.5) containing 0.05% Tween-20 (TTBS). The membranes were then incubated with primary antibody (anti-@4AchR, anti-A2 AchR, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 anti-@7AchR, anti-GADPH Santa Cruz) at appropriate dilutions in TTBS overnight at room temperature. After the membrane was washed with TTBS, secondary antibody (goat anti-rabbit IgG conjugated with biotin) was added for 1 hour. The membranes were washed with TTBS and then incubated with streptavidin-biotinylated alkaline phosphatase complex for 1 hour. After extensive washing with TTBS, the immunoreactive bands were visualized using 5-bromo-4-chloro-3-indolylphosphate/nitro-blue tetrazolium (BCIP/NBT) phosphatase substrate. Immunoreactive bands were scanned and analyzed with a digital scanning densitometer (personal densitometer, Molecular Dynamics, Sunnyvale, CA). Values for toluene-exposed rats were expressed as values relative to the average of controls, set at 100%.
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Statistical analysis
Basal body temperature and hot-plate nociceptive response were analyzed by student's t test. Comparisons between nicotine-induced hypothermia, and antinociception at different time points and were analyzed by two-way ANOVA with time as the repeated measure followed by Bonferroni post-test. Data for the occurrence of seizure signs were analyzed by Chi-square test. A value of P<0.05 was considered statistically significant.
Results
During the time of toluene exposure (PN 4-9 or PN 25-30), the body weight gain of the toluene-exposed (male: 12.5±1.2 g; 31.8±1.7 g; female: 11.6±1.2; 28.0±1.2) and control rats (male: 12.3±1.3 g, 29.1±2.0 g; female: 11.8±0.7, 28.8±0.5 ) was similar.
The nicotine-induced hypothermia was measured at PN56. As shown in Fig.1 Page 9 of 39 Toxicological Sciences Four convulsion signs, which occur in progression, myoclonic (MC) twitch; face and forelimb (FF) clonus; running and bouncing (RB) clonus; and tonic hindlimb extension (THE) were observed after administration of nicotine (20 mg/kg). As shown in Table 1 , the Chi-square test revealed the percentages of neonatal toluene-exposed rats expressing RB and THE were lower than those of control rats after nicotine challenge. Adolescent toluene exposure did not produce significant effect on nicotine-induced seizure susceptibility.
Finally, the neonatal exposure did not affect the levels of @4, A2 and @7 subunits examined in the prefrontal cortex, hippocampus, thalamus, striatum and cerebellum (Fig. 5 ).
Discussion
The main finding of this study was that toluene exposure during the brain growth 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 spurt (PN4-9), but not during adolescence (PN25-30), reduced the hypothermia, nociceptive and seizure responses to acute treatment with nicotine in both male and female rats. These results demonstrate that the brain growth spurt is more vulnerable than early adolescence to toluene exposure, reflecting the important principle that timing of exposure defines the insult and outcome. Given the brain growth spurt is a period during which many components of the developing brain are known to be exceedingly sensitive to neurotoxicants, it is possible that toluene exposure during this stage may damage the developing brain in such a way that it permanently alters certain behavioral responses to nicotine.
Although it is generally thought that the adolescence is a time of increased vulnerability to neurotoxicants, our results showed that toluene exposure during adolescence did not produce any effects on nicotine-induced behavioral responses, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12 growth spurt on nicotine-induced behavioral responses is attributed to a reduction in nicotine receptor number or activity after termination of toluene-mediated nicotine antagonism during this critical developmental period. It is well known that nAChRs belong to the large super family of ligand-gated ion channels and are expressed throughout both the central and peripheral nervous systems, and in non-neuronal cells.
Neuronal nAChRs are assembled from only the alpha (@2-9) and beta (A2-4) nicotinic subunits to form both homopentameric (e.g., @7) or heteropentameric (e.g., @4A2, @3A4*) ligand-gating cation channels and are expressed throughout both the central 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The present study presents initial evidence that toluene exposure during the brain growth spurt could disrupt several behavioral responses induced by nicotine. The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Table 1 . Effects of toluene exposure during the brain growth spurt and adolescence on nicotine-induced seizures
Percentage of rats expressing various seizure signs (%)
Toluene exposure at PN 4-9
Groups MC FF RB THE Control 100 (7/7) 85.7 (6/7) 85.7 (6/7) 28.5 (2/7) Male rats Toluene 100 (7/7) 100 (7/7) 14.3 (1/7)** 0 (0/7)
Control 100 (7/7) 100 (7/7) 71.4 (5/7) 42.8 (3/7) Female rats Toluene 100 (7/7) 100 (7/7) 14.3 (1/7)* 0 (0/7)* Toluene exposure at PN 25-30
Control 100 (7/7) 100 (7/7) 71.4 (5/7) 0 (0/7) Male rats Toluene 100 (7/7) 100 (7/7) 57.1 (4/7) 0 (0/7)
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